Top Legislation - View All
Also tagged in: Access to health care, Aged, Budgets, Business, Catastrophic health insurance, Child health, Children, Chronically ill, Congress, Congressional reporting requirements, Consumer education, Consumers, Drug approvals, Drug industry, Drugs, Education, Employee health benefits, Executive departments, Federal advisory bodies, Federal aid to child health services, Federal employees, Finance, Fines (Penalties), Flexible benefit plans, Fringe benefits, Government employees' health insurance, Government information, Government publicity, Government trust funds, Health education, Health information systems, Health insurance, Health policy, Higher education, Hospital care, Income tax, Insurance companies, Insurance premiums, Internet, Labor, Law, Living wills, Long-term care insurance, Medicaid, Medical care, Medical economics, Medical education, Medical instruments and apparatus, Medical malpractice, Medical records, Medical supplies, Medically uninsured, Medicare, Medicine, Physical examinations, Politics and government, Poor children, Prescription pricing, Preventive medicine, Public contracts, Quality of care, Retiree health benefits, Standards, State and local government, State politics and government, Tax credits, Tax deductions, Tax exclusion, Taxation, Technology, Telecommunication, Telephone, Terminal care, Web sites, Welfare
Latest Action: 04/24/2008 - S.AMDT.4577 Referred to the Committee on Finance. Bill TextA bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away. 1/18/2007--Introduced. Healthy Americans Act - Requires each adult individual to have the opportunity to purchase a Healthy Americans Private Insurance Plan (HAPI). Makes individuals who are not enrolled in another specified health plan and who are not opposed to coverage for religious reasons responsible for enrolling themselves and their dependent children in a HAPI plan offered through their state of residence. Sets forth penalties for failure to enroll. Establishes standardized coverage and state options for HAPI plans. Requires the Secretary of Health and Human Services to promulgate guidelines concerning the benefits, items, and services to be covered. Sets forth requirements for setting premiums. Requires the Secretary to establish the Healthy America Advisory Committee to provide annual recommendations concerning modifications to [...] show full description
Also tagged in: Administrative procedure, Auditing, Business, Cancer, Chemotherapy, Child health, Children, Clinical trials, Communication in medicine, Communications, Congress, Congressional reporting requirements, Consumers, Data banks, Department of Health and Human Services, Drug approvals, Drug industry, Executive departments, Fines (Penalties), Government information, Government paperwork, Government publicity, Governmental investigations, Health information systems, Identification devices, Law, Medical care, Medical instruments and apparatus, Medical research, Medical supplies, Medicine, National Institutes of Health (NIH), Nonprofit organizations, Periodicals, Product safety, Public contracts, Research centers, Science policy, Social services, Technology
Latest Action: 01/31/2007 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S1449-1454) Bill TextA bill to amend the Public Health Service Act to expand the clinical trials drug data bank. 1/31/2007--Introduced. Fair Access to Clinical Trials Act of 2007 or the FACT Act - Amends the Public Health Service Act to require the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health (NIH), to establish and operate a data bank of information on clinical trials, to include: (1) a clinical trials registry of health-related interventions conducted to test the safety or effectiveness of any drug, biological product, or device intended to treat serious or life-threatening diseases and conditions; and (2) a clinical trial results database of health-related interventions to test the safety or effectiveness of any drug, biological product, or device. Requires the Commissioner of Food and Drugs to make available to the public: (1) the full reviews conducted by the Food and Drug Administration (FDA) of new or supplemental new drug [...] show full description
Also tagged in: Accreditation (Medical care), Actions and defenses, Administrative fees, Administrative procedure, Administrative remedies, Aged, Appropriations, Armed forces, Auditing, Australia, Budgets, Business, Business records, Canada, Capital gains tax, Caribbean area, Checks, Citizenship, Civil liberties, Claims, Competitive bidding, Conflict of interests, Congress, Congressional reporting requirements, Consumer education, Consumers, Continental shelf, Contracts, Corporation taxes, Cost of living adjustments, Courts of special jurisdiction, Credit cards, Criminal justice, Cuba, Customs administration, Damages, Data banks, Defective products, Defense contracts, Defense economics, Department of Defense, Department of Health and Human Services, Department of Homeland Security, Department of the Interior, Department of the Treasury, Directories, Disciplining of employees, Dividends, Drug approvals, Drug industry, Drugs, Due process of law, East Asia, Education, Electronic commerce, Electronic data interchange, Electronic funds transfers, Electronic government information, Employee rights, Energy, Environmental Protection Agency, Europe, European Union, Evidence (Law), Executive departments, Expatriation, Export controls, Exports, Federal Emergency Management Agency, Federal employees, Federal officials, Federal preemption, Federal Trade Commission, Federal-state relations, Fees, Finance, Fines (Penalties), Food and Drug Administration (FDA), Foreign corporations, Foreign policy, Foreign tax credit, Forfeiture, Fraud, Gas in submerged lands, General Services Administration, Gifts, Government contractors, Government employees, Government information, Government paperwork, Government procurement, Government publicity, Government spending reductions, Governmental investigations, Gulf of Mexico, Health policy, Higher education, Identification devices, Immigration, Import restrictions, Imports, Income tax, Independent regulatory commissions, Indexing (Economic policy), Infrastructure, Infrastructure (Economics), Injunctions, Intellectual property, Intelligence activities, Interactive media, International broadcasting, Internet, Japan, Judicial review, Jurisdiction, Labeling, Latin America, Law, Legal fees, Liability (Law), Licenses, Lobbying, Medical associations, Medical care, Medical education, Medical records, Medical tests, Medicare, Medicine, Minimum tax, New Zealand, Oceania, Office of Government Ethics, Office of Management and Budget, Office of Special Counsel, Oil and gas leases, Oil and gas royalties, Oil well drilling, Overhead costs, Packaging, Parties to actions, Patent infringement, Patents, Petroleum in submerged lands, Pharmaceutical research, Pharmacies, Pharmacists, Physical examinations, Politics and government, Prescription pricing, Presidential appointments, Presidents, Price discrimination, Product counterfeiting, Profit, Public contracts, Restrictive trade practices, Right of privacy, Science policy, Security clearances, State and local government, State laws, Sunset legislation, Surety and fidelity, Switzerland, Tax deductions, Tax deferral, Tax exclusion, Tax exemption, Tax liens, Tax rates, Tax shelters, Taxation of foreign income, Technology, Telecommunication, Telephone, Television broadcasting, Trade, User charges, Web sites, Whistle blowing, Wholesale trade
Latest Action: 02/12/2007 - Sponsor introductory remarks on measure. (CR S1855-1857) Bill TextA bill to reduce the Federal budget deficit, and for other purposes. 2/12/2007--Introduced. Act for Our Kids - Repeals the Television Broadcasting to Cuba Act. Amends the Cuban Liberty and Democratic Solidarity (LIBERTAD) Act of 1996 to prohibit federal funding of television broadcasting to Cuba. Terminates the U.S. Court of Federal Claims. Requires federal agencies to reduce administrative expenses. Eliminates the Medicare Advantage Regional Plan Stabilization (SLUSH) Fund. Amends the federal criminal code to prohibit profiteering and fraud involving a contract or the provision of goods or services in connection with a war or military action. Requires: (1) suspension and debarment of unethical contractors; (2) disclosure by federal agencies, upon request, to the appropriate committee chairman or ranking member of audit reports regarding federal contractors; and (3) public access to information on federal contractor penalties and [...] show full description
Also tagged in: Administrative procedure, Administrative remedies, Arthritis, Bone fractures, Calcium, Cardiovascular diseases, Communication in medicine, Communication in science, Communications, Conflict of interests, Consumers, Deceptive advertising, Department of Health and Human Services, Dietary supplements, Evidence (Law), Executive departments, Federal advisory bodies, Federal Trade Commission, Food, Food labeling, Government information, Government publications, Governmental investigations, Independent regulatory commissions, Labeling, Law, Medical care, Medicinal plants, Medicine, Nutrition, Oils and fats, Periodicals, Preventive medicine, Science policy
Latest Action: 05/02/2007 - Referred to the Subcommittee on Health. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act concerning foods and dietary supplements, to amend the Federal Trade Commission Act concerning the burden of proof in false advertising cases, and for other purposes. 5/2/2007--Introduced. Health Freedom Protection Act - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to provide that a food or dietary supplement is not a drug solely because the label or labeling contains a claim to cure, mitigate, treat, or prevent disease. Prohibits the Secretary of Health and Human Services from: (1) restricting the reprinting and distribution or sale of any U.S. government publication or any accurate quotations of such a publication, including content concerning nutrients and disease treatment or prevention; or (2) construing the distribution or sale of, or accurate quotation from, such a publication in connection with the sale of a food or dietary supplement as evidence of an intent to sell that food or dietary supplement [...] show full description
Also tagged in: Administrative fees, Animals, Budgets, Business, Clinical trials, Communication in medicine, Communications, Conflict of interests, Consumer education, Consumer protection, Consumers, Data banks, Department of Health and Human Services, Drug approvals, Drug industry, Drugs, Executive departments, Executive reorganization, Federal advisory bodies, Federal-state relations, Fines (Penalties), Food and Drug Administration (FDA), Government and business, Government ethics, Government information, Government publicity, Health education, Health information systems, Health policy, Informed consent (Medical law), Labeling, Law, Medical care, Medical ethics, Medical instruments and apparatus, Medical research, Medical supplies, Medicine, Parties to actions, Physicians, Politics and government, Product safety, Products liability, Science policy, State and local government, State courts, State laws, Technology, Veterinary medicine, Warning labels
Latest Action: 05/10/2007 - Referred to the House Committee on Energy and Commerce. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug Administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes. 5/10/2007--Introduced. Food and Drug Administration Improvement Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require that all fees collected for the review of applications for human drugs, devices, and animal drugs be deposited in the general fund of the Treasury. Makes available amounts necessary for the Secretary of Health and Human Services to review such applications. Prohibits the Secretary from entering into agreements with persons [...] show full description
Also tagged in: Business, Civil liberties, Consumers, Drug industry, Drugs, Fines (Penalties), Government information, Government publicity, Identification devices, Intellectual property, Labeling, Law, Medical care, Medicine, Packaging, Product counterfeiting, Right of privacy, Technology
Latest Action: 06/14/2007 - Referred to the Subcommittee on Health. Bill TextTo direct the Secretary of Health and Human Services to require the incorporation of counterfeit-resistant technologies into the packaging of prescription drugs, and for other purposes. 6/14/2007--Introduced. Reducing Fraudulent and Imitation Drugs Act of 2007 - Directs the Secretary of Health and Human Services to require prescription drug packaging to incorporate: (1) radio frequency tagging technology or similar trace and track technologies; (2) tamper-indicating technologies; and (3) blister security packaging when possible. Directs the Secretary to: (1) require that such technologies be used exclusively to authenticate the pedigree of prescription drugs; and (2) prohibit such technologies from containing or transmitting any identifying information of a health care practitioner or consumer, or any advertisement or information about indications or off-label uses. Requires the Secretary to encourage prescription drug manufacturers and distributors to incorporate: [...] show full description
Also tagged in: Business, Communications, Consumer education, Consumers, Corporation taxes, Deceptive advertising, Drug industry, Drugs, Government information, Government paperwork, Income tax, Labeling, Medical care, Medicine, Tax deductions, Taxation
Latest Action: 06/21/2007 - Referred to the Subcommittee on Health. Bill TextTo amend the Internal Revenue Code of 1986 to deny any deduction for direct-to-consumer advertisements of prescription drugs that fail to provide certain information or to present information in a balanced manner, to amend the Federal Food, Drug, and Cosmetic Act to require reports regarding such advertisements, and to amend such Code to deny any deduction for direct-to-consumer advertisements of qualified prescription drugs for a two-year period. 6/21/2007--Introduced. Fair Balance Prescription Drug Advertisement Act of 2007 - Amends the Internal Revenue Code to disallow a tax deduction for: (1) expenses for direct-to-consumer prescription drug advertising that fails to provide adequate information on drug side effects, contraindications, or lack of effectiveness; and (2) expenses for direct-to-consumer prescription drug advertising of a new drug, a new combination of active substances, or a new delivery system for an existing drug for a two-year period after the introduction [...] show full description
Also tagged in: Access to health care, Administrative fees, Administrative procedure, Administrative remedies, Animals, Antibiotics, Authorization, Budgets, Business, Cancer, Child health, Children, Civil liberties, Clinical trials, Communications, Computer security measures, Conflict of interests, Congressional investigations, Congressional reporting requirements, Consumer education, Consumers, Cosmetics, Data banks, Deceptive advertising, Department of Health and Human Services, Directories, Drug approvals, Drug industry, Drug interactions, Drugs, Electronic data interchange, Electronic government information, Executive departments, Executive reorganization, Federal advisory bodies, Federal aid to research, Food, Food and Drug Administration (FDA), Food safety, Foreign corporations, Foundations, Fund raising, Gifts, Government information, Government paperwork, Government publicity, Health information systems, Health policy, Identification devices, Imaging systems in medicine, Imports, Intellectual property, Inventions, Inventors, Labeling, Law, Licenses, Medical care, Medical ethics, Medical innovations, Medical instruments and apparatus, Medical records, Medical research, Medical supplies, Medicine, National Institutes of Health (NIH), Nonprofit organizations, Nosocomial infections, Nuclear medicine, Orphan drugs, Patents, Pediatrics, Performance measurement, Pharmaceutical research, Physicians, Product counterfeiting, Product development, Product safety, Profit, Public-private partnerships, Research and development, Research grants, Right of privacy, Risk, Science policy, Small business, Social services, Technology, Telecommunication, Telephone, Television advertising, Trade, User charges, Veterinary medicine
Latest Action: 07/16/2007 - Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 270. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes. 7/11/2007--Passed House amended. (There is 1 other summary) Food and Drug Administration Amendments Act of 2007 - Title I: Prescription Drug User Fee Amendments of 2007 - (Sec. 101) Prescription Drug User Fee Amendments of 2007 - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to include postmarket safety activities within the process for the review of human drug applications or supplements, including: (1) developing and using improved adverse event data collection systems and improved analytical tools to assess potential safety problems; (2) implementing and enforcing provisions relating to postapproval studies, clinical trials, labeling changes, and risk [...] show full description
Also tagged in: Accreditation (Medical care), Actions and defenses, Administrative fees, Administrative procedure, Administrative remedies, Australia, Budgets, Business, Business records, Canada, Checks, Civil liberties, Congress, Congressional reporting requirements, Consumer education, Consumers, Contracts, Credit cards, Criminal justice, Customs administration, Damages, Defective products, Department of Health and Human Services, Directories, Drug approvals, Drug industry, Drugs, East Asia, Education, Electronic commerce, Electronic data interchange, Electronic funds transfers, Electronic government information, Europe, European Union, Evidence (Law), Executive departments, Export controls, Exports, Federal preemption, Federal Trade Commission, Federal-state relations, Finance, Fines (Penalties), Food and Drug Administration (FDA), Forfeiture, Fraud, Government information, Government paperwork, Government publicity, Governmental investigations, Higher education, Identification devices, Import restrictions, Imports, Independent regulatory commissions, Injunctions, Intellectual property, Interactive media, Internet, Japan, Labeling, Law, Liability (Law), Licenses, Medical associations, Medical care, Medical education, Medical records, Medical tests, Medicine, New Zealand, Oceania, Packaging, Parties to actions, Patent infringement, Patents, Pharmaceutical research, Pharmacies, Pharmacists, Physical examinations, Prescription pricing, Price discrimination, Product counterfeiting, Restrictive trade practices, Right of privacy, Science policy, State and local government, State laws, Surety and fidelity, Switzerland, Technology, Telecommunication, Telephone, Trade, User charges, Web sites, Wholesale trade
Latest Action: 03/07/2007 - Committee on Commerce, Science, and Transportation Subcommittee on Interstate Commerce, Trade, and Tourism. Hearings held. Bill TextA bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. 1/10/2007--Introduced. Pharmaceutical Market Access and Drug Safety Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise provisions governing the importation of prescription drugs. Waives the limitation on importation of prescription drugs that have been exported from the United States. Prohibits the importation of a qualifying drug unless such drug is imported by: (1) a registered importer; or (2) an individual for personal use. Establishes registration conditions for importers and exporters. Requires the Secretary to inspect places of business, verify chains of custody, inspect facilities, and determine compliance with registration conditions. Sets forth provisions governing the importation of qualifying drugs that are different from U.S. label drugs, including standards for judging such differences.[...] show full description
Also tagged in: Accreditation (Medical care), Actions and defenses, Administrative fees, Administrative procedure, Administrative remedies, Australia, Budgets, Business, Business records, Canada, Checks, Civil liberties, Congress, Congressional reporting requirements, Consumer education, Consumers, Contracts, Credit cards, Criminal justice, Customs administration, Damages, Defective products, Department of Health and Human Services, Directories, Drug approvals, Drug industry, Drugs, East Asia, Education, Electronic commerce, Electronic data interchange, Electronic funds transfers, Electronic government information, Europe, European Union, Evidence (Law), Executive departments, Export controls, Exports, Federal preemption, Federal Trade Commission, Federal-state relations, Finance, Fines (Penalties), Food and Drug Administration (FDA), Forfeiture, Fraud, Government information, Government paperwork, Government publicity, Governmental investigations, Higher education, Identification devices, Import restrictions, Imports, Independent regulatory commissions, Injunctions, Intellectual property, Interactive media, Internet, Japan, Labeling, Law, Liability (Law), Licenses, Medical associations, Medical care, Medical education, Medical records, Medical tests, Medicine, New Zealand, Oceania, Packaging, Parties to actions, Patent infringement, Patents, Pharmaceutical research, Pharmacies, Pharmacists, Physical examinations, Prescription pricing, Price discrimination, Product counterfeiting, Restrictive trade practices, Right of privacy, Science policy, State and local government, State laws, Surety and fidelity, Switzerland, Technology, Telecommunication, Telephone, Trade, User charges, Web sites, Wholesale trade
Latest Action: 02/02/2007 - Referred to the Subcommittee on Health. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. 1/10/2007--Introduced. Pharmaceutical Market Access and Drug Safety Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise provisions governing the importation of prescription drugs. Waives the limitation on importation of prescription drugs that have been exported from the United States. Prohibits the importation of a qualifying drug unless such drug is imported by: (1) a registered importer; or (2) an individual for personal use. Establishes registration conditions for importers and exporters. Requires the Secretary to inspect places of business, verify chains of custody, inspect facilities, and determine compliance with registration conditions. Sets forth provisions governing the importation of qualifying drugs that are different from U.S. label drugs, including standards for judging such differences.[...] show full description
|
Latest Legislation - View All
Also tagged in: Access to health care, Administrative fees, Administrative procedure, Administrative remedies, Agriculture, Animals, Antibiotics, Aquaculture, Authorization, Authors and authorship, Budgets, Business, Child health, Children, Civil liberties, Clinical trials, Communicable diseases, Communication in medicine, Communication in science, Communications, Conflict of interests, Congress, Congressional investigations, Congressional reporting requirements, Consumer education, Consumers, Cosmetics, Criminal justice, Criminal justice information, Data banks, Deceptive advertising, Department of Health and Human Services, Direct mail advertising, Directories, Drug approvals, Drug industry, Drug resistance in microorganisms, Drugs, Electronic data interchange, Electronic government information, Emergency communication systems, Emergency management, Employee training, Environmental assessment, Environmental protection, Executive departments, Executive reorganization, Eye diseases, Federal advisory bodies, Federal employees, Federal officials, Federal preemption, Financial disclosure, Fines (Penalties), Food and Drug Administration (FDA), Food labeling, Food safety, Foundations, Fund raising, Generic drugs, Genetic engineering, Genetic research, Gifts, Government employees, Government information, Government paperwork, Government publicity, Grants-in-aid, Hazardous substances, Health information systems, Health policy, Health surveys, Humanities, Identification devices, Imports, Intellectual property, Internet, Inventors, Job training, Labeling, Law, Local laws, Medical associations, Medical care, Medical ethics, Medical instruments and apparatus, Medical supplies, Medicine, Nonprofit organizations, Nosocomial infections, Orphan drugs, Patents, Pediatrics, Peer review organizations (Medicine), Performance measurement, Pesticides, Pharmaceutical research, Physicians, Product counterfeiting, Product development, Product safety, Public contracts, Public meetings, Public-private partnerships, Radioisotopes in medicine, Research and development, Research grants, Right of privacy, Risk, Science policy, Scientists in government, Seafood, Skin cancer, Small business, Social services, Standards, State and local government, State laws, Technology, Telecommunication, Television advertising, Terrorism, Trade, Trade agreements, Trade negotiations, User charges, Veterinary medicine, Warning labels
Latest Action: 09/27/2007 - Signed by President. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes. 9/27/2007--Public Law. (There is 1 other summary) (This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)Food and Drug Administration Amendments Act of 2007 - Title I: Prescription Drug User Fee Amendments of 2007 - (Sec. 101) Prescription Drug User Fee Amendments of 2007 - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to include postmarket safety activities within the process for the review of human drug applications or supplements, including: (1) developing and using improved adverse event data collection systems and improved analytical tools to assess potential [...] show full description
Also tagged in: Access to health care, Administrative fees, Administrative procedure, Administrative remedies, Animals, Antibiotics, Authorization, Budgets, Business, Cancer, Child health, Children, Civil liberties, Clinical trials, Communications, Computer security measures, Conflict of interests, Congressional investigations, Congressional reporting requirements, Consumer education, Consumers, Cosmetics, Data banks, Deceptive advertising, Department of Health and Human Services, Directories, Drug approvals, Drug industry, Drug interactions, Drugs, Electronic data interchange, Electronic government information, Executive departments, Executive reorganization, Federal advisory bodies, Federal aid to research, Food, Food and Drug Administration (FDA), Food safety, Foreign corporations, Foundations, Fund raising, Gifts, Government information, Government paperwork, Government publicity, Health information systems, Health policy, Identification devices, Imaging systems in medicine, Imports, Intellectual property, Inventions, Inventors, Labeling, Law, Licenses, Medical care, Medical ethics, Medical innovations, Medical instruments and apparatus, Medical records, Medical research, Medical supplies, Medicine, National Institutes of Health (NIH), Nonprofit organizations, Nosocomial infections, Nuclear medicine, Orphan drugs, Patents, Pediatrics, Performance measurement, Pharmaceutical research, Physicians, Product counterfeiting, Product development, Product safety, Profit, Public-private partnerships, Research and development, Research grants, Right of privacy, Risk, Science policy, Small business, Social services, Technology, Telecommunication, Telephone, Television advertising, Trade, User charges, Veterinary medicine
Latest Action: 07/16/2007 - Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 270. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes. 7/11/2007--Passed House amended. (There is 1 other summary) Food and Drug Administration Amendments Act of 2007 - Title I: Prescription Drug User Fee Amendments of 2007 - (Sec. 101) Prescription Drug User Fee Amendments of 2007 - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to include postmarket safety activities within the process for the review of human drug applications or supplements, including: (1) developing and using improved adverse event data collection systems and improved analytical tools to assess potential safety problems; (2) implementing and enforcing provisions relating to postapproval studies, clinical trials, labeling changes, and risk [...] show full description
Also tagged in: Business, Communications, Consumer education, Consumers, Corporation taxes, Deceptive advertising, Drug industry, Drugs, Government information, Government paperwork, Income tax, Labeling, Medical care, Medicine, Tax deductions, Taxation
Latest Action: 06/21/2007 - Referred to the Subcommittee on Health. Bill TextTo amend the Internal Revenue Code of 1986 to deny any deduction for direct-to-consumer advertisements of prescription drugs that fail to provide certain information or to present information in a balanced manner, to amend the Federal Food, Drug, and Cosmetic Act to require reports regarding such advertisements, and to amend such Code to deny any deduction for direct-to-consumer advertisements of qualified prescription drugs for a two-year period. 6/21/2007--Introduced. Fair Balance Prescription Drug Advertisement Act of 2007 - Amends the Internal Revenue Code to disallow a tax deduction for: (1) expenses for direct-to-consumer prescription drug advertising that fails to provide adequate information on drug side effects, contraindications, or lack of effectiveness; and (2) expenses for direct-to-consumer prescription drug advertising of a new drug, a new combination of active substances, or a new delivery system for an existing drug for a two-year period after the introduction [...] show full description
Also tagged in: Business, Civil liberties, Consumers, Drug industry, Drugs, Fines (Penalties), Government information, Government publicity, Identification devices, Intellectual property, Labeling, Law, Medical care, Medicine, Packaging, Product counterfeiting, Right of privacy, Technology
Latest Action: 06/14/2007 - Referred to the Subcommittee on Health. Bill TextTo direct the Secretary of Health and Human Services to require the incorporation of counterfeit-resistant technologies into the packaging of prescription drugs, and for other purposes. 6/14/2007--Introduced. Reducing Fraudulent and Imitation Drugs Act of 2007 - Directs the Secretary of Health and Human Services to require prescription drug packaging to incorporate: (1) radio frequency tagging technology or similar trace and track technologies; (2) tamper-indicating technologies; and (3) blister security packaging when possible. Directs the Secretary to: (1) require that such technologies be used exclusively to authenticate the pedigree of prescription drugs; and (2) prohibit such technologies from containing or transmitting any identifying information of a health care practitioner or consumer, or any advertisement or information about indications or off-label uses. Requires the Secretary to encourage prescription drug manufacturers and distributors to incorporate: [...] show full description
Also tagged in: Administrative fees, Animals, Budgets, Business, Clinical trials, Communication in medicine, Communications, Conflict of interests, Consumer education, Consumer protection, Consumers, Data banks, Department of Health and Human Services, Drug approvals, Drug industry, Drugs, Executive departments, Executive reorganization, Federal advisory bodies, Federal-state relations, Fines (Penalties), Food and Drug Administration (FDA), Government and business, Government ethics, Government information, Government publicity, Health education, Health information systems, Health policy, Informed consent (Medical law), Labeling, Law, Medical care, Medical ethics, Medical instruments and apparatus, Medical research, Medical supplies, Medicine, Parties to actions, Physicians, Politics and government, Product safety, Products liability, Science policy, State and local government, State courts, State laws, Technology, Veterinary medicine, Warning labels
Latest Action: 05/10/2007 - Referred to the House Committee on Energy and Commerce. Bill TextTo amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug Administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes. 5/10/2007--Introduced. Food and Drug Administration Improvement Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require that all fees collected for the review of applications for human drugs, devices, and animal drugs be deposited in the general fund of the Treasury. Makes available amounts necessary for the Secretary of Health and Human Services to review such applications. Prohibits the Secretary from entering into agreements with persons [...] show full description
Also tagged in: Administrative procedure, Administrative remedies, Arthritis, Bone fractures, Calcium, Cardiovascular diseases, Communication in medicine, Communication in science, Communications, Conflict of interests, Consumers, Deceptive advertising, Department of Health and Human Services, Dietary supplements, Evidence (Law), Executive departments, Federal advisory bodies, Federal Trade Commission, Food, Food labeling, Government information, Government publications, Governmental investigations, Independent regulatory commissions, Labeling, Law, Medical care, Medicinal plants, Medicine, Nutrition, |